Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2

OBJECTIVE: To evaluate the efficacy of ustekinumab by prior treatment exposure and disease duration in tumour necrosis factor inhibitor (TNF)-naïve patients with psoriatic arthritis (PsA) in the PSUMMIT 1 and PSUMMIT 2 studies. METHODS: In the phase 3, randomised, placebo-controlled PSUMMIT 1 and PS...

Descripción completa

Detalles Bibliográficos
Autores principales: McInnes, Iain B, Chakravarty, Soumya D, Apaolaza, Isabel, Kafka, Shelly, Hsia, Elizabeth C, You, Yin, Kavanaugh, Arthur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744084/
https://www.ncbi.nlm.nih.gov/pubmed/31565242
http://dx.doi.org/10.1136/rmdopen-2019-000990

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744084/
https://www.ncbi.nlm.nih.gov/pubmed/31565242
http://dx.doi.org/10.1136/rmdopen-2019-000990

Ejemplares similares